Astrazeneca Plc (AZN)
$48.36 0.44 (0.92%)
18:30 EST AZN Stock Quote Delayed 15 Minutes
Previous Close $48.36
Market Cap 122.51B
PE Ratio 43.65
Volume (Avg. Vol.) 1.83M
Day's Range 48.20 - 48.59
52-Week Range 35.30 - 49.22
Dividend & Yield 1.37 (2.83%)
AZN Stock Predictions, Articles, and Astrazeneca Plc News
- From InvestorPlace
- From the Web
Amarin is targeting a huge market, and its main drug -- Vascepa -- is likely to be expanded in its coverage. Here’s a look at what’s ahead for the stock.
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
The stock charts of PGR, LB and PKG are going to start the new trading week on the cusp of major moves that have been forming for weeks.
AstraZeneca announced that it has inked a deal with Daiichi Sankyo to improve its oncology branch. AZN stock is down more than 5% on Friday.
An AstraZeneca earnings beat for the pharmaceutical company's fourth quarter of 2018 has AZN stock heading higher on Thursday.
Don't ignore Dow Jones stocks. They can still power your portfolio. Here are 5 of the best to own in 2019 and beyond!
AstraZeneca's profits are poised to accelerate, but investors should wait for AZN stock to break out of its range before buying the shares.
BIIB stock jumped on Friday, and for good reason. It's not a buy at these lofty levels, but Biogen has at least earned a spot on your watchlist.
Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well. Compare Brokers....
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
AstraZeneca plc (AZN) stock was down on Friday following the release of its earnings report for the first quarter of 2018.
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by....
Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now.
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. With unique fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. The current Portfolio Grader recommendation on the shares has been in place for the last month.
AstraZeneca Plc (NYSE:AZN) is a $83.3 billion in market value constituent of the Pharmaceuticals GICS industry group where the ranking for AZN by Portfolio Grader places it 37 among the 132 companies in this industry group, giving it an above-average position. AZN is ranked in the top half of the sector with a ranking of 267 among the 782 companies in the sector and number 1,662 in the 5000 company Portfolio Grader company universe.
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. The methodology for investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.
AstraZeneca Plc (NYSE:AZN) is ranked as a Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methods. The shares have been upgraded from a Hold to a Buy in the last week.
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Hold. Using Louis Navellier's investing methodology, this analytical tool assesses stocks with fundamental and quantitative analytical tools. AZN has maintained this ranking for the last month.
From Talk Markets
Navellier RatingsPowered by Portfolio Grader